← FDA DRUG APPROVALS

FDA ANDA · ANDA219241

OXCARBAZEPINE

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA219241
TYPE
ANDA
ORIGINAL APPROVAL
2025-04-30
LATEST ACTION
2025-04-30
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

OXCARBAZEPINEDiscontinued
OXCARBAZEPINE 300MG · TABLET, EXTENDED RELEASE · ORAL
OXCARBAZEPINEDiscontinued
OXCARBAZEPINE 600MG · TABLET, EXTENDED RELEASE · ORAL
OXCARBAZEPINEDiscontinued
OXCARBAZEPINE 150MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2025-04-30UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →